The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences Inc. is preparing to engage with industry peers and potential partners at the upcoming BIO2026 conference in San Diego. The company is encouraging participants in the genetic medicine sector to initiate conversations around platform partnerships and its development pipeline.
This outreach underscores Solid Biosciences Inc.'s strategic focus on collaboration within the gene therapy and biotechnology innovation landscape. The company aims to foster new connections and discuss opportunities that may expand its presence and impact in the field.
View post on X Loading...
Solid Biosciences Inc. recently presented clinical insights on its SGT-003 gene therapy candidate for Duchenne muscular dystrophy at a leading scientific congress, according to a company update. The firm also strengthened its relationship with the Jett Foundation as a sponsor of the organization’s 25th Anniversary Silver Soirée earlier this month, as noted in a prior announcement. These activities highlight Solid’s ongoing engagement within both the scientific and patient communities.